Incidence of Morphine-Induced Constipation
Constipation occurs in 40-80% of patients taking chronic opioid therapy, with some degree of constipation being near-universal in patients on morphine and other opioids 1.
Specific Incidence Data
The incidence of opioid-induced constipation (OIC) varies based on the population studied and definition used:
- General opioid users: 40-80% develop OIC during chronic therapy 1
- Cancer patients on oral morphine: 72% experience constipation 2
- Chronic non-cancer pain patients: 28% meet Rome IV diagnostic criteria for OIC, with 40% reporting self-assessed constipation after starting opioids 3
- Emergency department presentations: 6.4% of long-acting opioid users present with OIC 4
- Cancer patients starting strong opioids: 66% develop OIC within 2 weeks of initiation, even at low doses 5
Key Clinical Considerations
The development of constipation is near-universal and dose-independent. The 2019 AGA guidelines explicitly state that "some degree of constipation is near universal in patients taking opioid medications" 1. This is critical because:
- Unlike other opioid side effects (nausea, sedation), constipation does not develop tolerance and persists throughout therapy 6
- Even low-dose morphine causes significant constipation—66% of cancer patients developed OIC within 2 weeks regardless of dose 5
- The FDA label for morphine lists constipation as one of the most frequent adverse reactions seen on initiation 7
Mechanism and Clinical Impact
Morphine causes constipation through μ-opioid receptor activation in the gastrointestinal tract, resulting in:
- Increased non-propulsive contractions
- Increased colonic fluid absorption and stool desiccation
- Increased anal sphincter tone
- Reduced rectal sensory threshold 1
This mechanism explains why constipation is essentially inevitable and requires proactive management from the start of therapy, not reactive treatment after symptoms develop 6.
Important Caveats
- Constipation is poorly managed in practice: 89% of constipated cancer patients on morphine were receiving inadequate laxative therapy 2
- Individual variation exists: Some patients require no laxatives, others need high-dose laxatives, but the majority (72-80%) will develop symptoms 2
- The incidence may be underestimated because OIC is defined variably across studies, and some definitions focus only on stool frequency rather than the full constellation of symptoms (straining, hard stools, incomplete evacuation) 1